Lack of association between TGF-β-1 genotypes and microalbuminuria in essential hypertensive men

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1864-1869

  Dell'Omo, Giulia ^a   Penno, Giuseppe ^a   Pucci, Laura ^a   Lucchesi, Daniela ^a   Del Prato, Stefano ^a   Pedrinelli, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Angiotensin converting enzyme deletioninsertion polymorphism; Circulating TGF 1 levels; Hypertensive target organ damage; Microalbuminuria; TGF 1 polymorphisms

Indexed keywords

5' NUCLEOTIDASE; ALBUMIN; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; ISOLEUCINE; LEUCINE; LIPID; PROLINE; THREONINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ALBUMINURIA; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR PARAMETERS; CAUCASIAN; CIRCULATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEART LEFT VENTRICLE MASS; HOMOZYGOTE; HUMAN; IMMUNOASSAY; IN VIVO STUDY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MICROALBUMINURIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS;

ADULT; ALBUMINURIA; ALLELES; AMINO ACID SUBSTITUTION; BASE SEQUENCE; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; INDEL MUTATION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67651095959     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn754     Document Type: Article

References (40)

1. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-404
2. Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. Am J Hypertens 2003; 16: 604-611
3. Grainger DJ. TGF-beta and atherosclerosis in man. Cardiovasc Res 2007; 74: 213-222
4. Ketteler M, Noble NA, Border WA. Increased expression of transforming growth factor-beta in renal disease. Curr Opin Nephrol Hypertens 1994; 3: 446-452
5. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517-522
6. Scaglione R, Argano C, Parrinello G et al. Relationship between transforming growth factor beta1 and progression of hypertensive renal disease. J Hum Hypertens 2002; 16: 641-645
7. Pedrinelli R, Dell'Omo G, Di Bello V et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79-89
8. Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18
9. Pedrinelli R, Dell'Omo G, Di Bello V et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24: 2414-2419
10. Freedman BI, Beck SR, Rich SS et al. A genome-wide scan for urinary albumin excretion in hypertensive families. Hypertension 2003; 42: 291-296
11. Cambien F, Ricard S, Troesch A et al. Polymorphisms of the trans-forming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996; 28: 881-887
12. Grainger DJ, Heathcote K, Chiano M et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93-97
13. Silverman ES, Palmer LJ, Subramaniam V et al. Transforming growth factor-β1 promoter polymorphism C-509T is associated with asthma. AmJ Respir Crit Care Med 2004; 169: 214-219
14. Suthanthiran M, Li B, Song JO et al. Transforming growth factor-β1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97: 3479-3484
15. Yokota M, Ichihara S, Lin TL et al. Association of a T29->C poly-morphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-2787
16. Awad MR, El-Gamel A, Hasleton P et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020
17. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31(Pt 2): 181-188
18. Pontremoli R, Sofia A, Tirotta A et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7: 2550-2558
19. Kario K, Kanai N, Nishiuma S et al. Hypertensive nephropathy and the gene for angiotensin-converting enzyme. Arterioscler Thromb Vasc Biol 1997; 17: 252-256
20. Wang XL, Sim AS, Wilcken DE. A common polymorphism of the transforming growth factor-beta1 gene and coronary artery disease. Clin Sci (Lond) 1998; 95: 745-746
21. Wood NA, Thomson SC, Smith RM et al. Identification of human TGF-beta1 signal (leader) sequence polymorphisms by PCR-RFLP. J Immunol Methods 2000; 234: 117-122
22. Pociot F, Hansen PM, Karlsen AE et al. TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. JAm Soc Nephrol 1998; 9: 2302-2307
23. Pedrinelli R, Dell'Omo G, Penno G et al. Alpha-adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. J Hypertens 2006; 24: 931-937
24. de Simone G, Devereux RB, Daniels SR et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062
25. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K et al. The Copenhagen City Heart Study Group. Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic subjects. Scand J Clin Lab Invest 1993; 53: 867-872
26. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366: 1315-1323
27. Akai Y, Sato H, Ozaki H et al. Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am J Kidney Dis 2001; 38(suppl 1): S182-S185
28. Ng DP, Warram JH, Krolewski AS. TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am J Kidney Dis 2003; 41: 22-28
29. Syrris P, Carter ND, Metcalfe JC et al. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Lond) 1998; 95: 659-667
30. Patel A, Scott WR, Lympany PA et al. Warren 3/UK Go Kind Study Group. The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in type 1 diabetes. Diabet Med 2005; 22: 69-73
31. Yamada Y, Miyauchi A, Takagi Y et al. Association of the C-509→T polymorphism, alone of in combination with the T869→C polymor-phism, of the transforming growth factor-beta1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. JMolMed 2001; 79: 149-156
32. Mak JC, Leung HC, Sham AS et al. Genetic polymorphisms and plasma levels of transforming growth factor-beta(1) in Chinese patients with tuberculosis in Hong Kong. Cytokine 2007; 40: 177-182
33. Pinto YM, Pinto-Sietsma SJ, Philipp T et al. Reduction in left ventricular messenger RNA for transforming growth factor 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 rat. Hypertension 2000; 36: 747-754
34. Dell'Omo G, Penno G, Pucci L et al. Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. J Hypertens 2007; 25: 1389-1395
35. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346
36. Muller DN, Bohlender J, Hilgers KF et al. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 1997; 29: 98-104
37. Ueda S, Elliott HL, Morton JJ et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995; 25: 1266-1269
38. Ruiz-Ortega M, Esteban V, Ruperez M et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006; 15: 159-166
39. Baldoncini R, Desideri G, Bellini C et al. High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. Kidney Int 1999; 56: 1499-1504
40. Cha DR, Kim IS, Kang YS et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with type 2 diabetes mellitus. Diabet Med 2005; 22: 14-20